R Scott Mackin1, Philip S Insel2, Susan Landau3, David Bickford4, Ruth Morin5, Emma Rhodes5, Duygu Tosun6, Howie J Rosen7, Meryl Butters8, Paul Aisen9, Rema Raman9, Andrew Saykin10, Arthur Toga11, Clifford Jack12, Robert Koeppe13, Michael W Weiner14, Craig Nelson4. 1. Department of Psychiatry, University of California, San Francisco, California; Center for Imaging of Neurodegenerative Diseases, Veterans Administration Medical Center, San Francisco, California. Electronic address: scott.mackin@ucsf.edu. 2. Department of Psychiatry, University of California, San Francisco, California; Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden. Electronic address: philipinsel@gmail.com. 3. Helen Wills Neuroscience Institute, University of California, Berkeley, California. 4. Department of Psychiatry, University of California, San Francisco, California. 5. Center for Imaging of Neurodegenerative Diseases, Veterans Administration Medical Center, San Francisco, California. 6. Department of Radiology, University of California, San Francisco, California; Center for Imaging of Neurodegenerative Diseases, Veterans Administration Medical Center, San Francisco, California. 7. Memory and Aging Center, Department of Neurology, University of California, San Francisco, California. 8. Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 9. Department of Neurology, University of Southern California, San Diego, California; Alzheimer's Therapeutic Research Institute, San Diego, California. 10. Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, Indiana. 11. Laboratory of Neuro Imaging, Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Los Angeles, California. 12. Mayo Clinic, Rochester, Minnesota. 13. Department of Radiology, University of Michigan, Ann Arbor, Michigan. 14. Department of Psychiatry, University of California, San Francisco, California; Department of Radiology, University of California, San Francisco, California; Center for Imaging of Neurodegenerative Diseases, Veterans Administration Medical Center, San Francisco, California.
Abstract
BACKGROUND: We evaluated the role of cortical amyloid deposition as a factor contributing to memory dysfunction and increased risk of dementia associated with late-life depression (LLD). METHODS: A total of 119 older adult participants with a current diagnosis of major depression (LLD) from the Alzheimer's Disease Neuroimaging Initiative (ADNI) Depression Project study and 119 nondepressed (ND) cognitively unimpaired participants matched on age, sex, and APOE genotype were obtained from the ADNI database. RESULTS: Thirty-three percent of LLD participants met ADNI criteria for mild cognitive impairment. Compared with ND individuals, the LLD group exhibited less global amyloid beta (Aβ) accumulation (p = .05). The proportion of amyloid positivity in the LLD group was 19.3% compared with 31.1% for the ND participants (p = .02). Among LLD participants, global Aβ was not associated with lifetime number of depressive episodes, lifetime length of depression, length of lifetime selective serotonin reuptake inhibitor use, or lifetime length of untreated depression (p > .21 for all). Global Aβ was associated with worse memory performance (p = .05). Similar results were found in secondary analyses restricting comparisons to the cognitively unimpaired LLD participants as well as when comparing the LLD group with an ND group that included participants with mild cognitive impairment. CONCLUSIONS: Contrary to expectation, the LLD group showed less Aβ deposition than the ND group and Aβ deposition was not associated with depression history characteristics. Aβ was associated with memory, but this relationship did not differ between LLD and ND. Our results suggest that memory deficits and accelerated cognitive decline reported in previous studies of LLD are not due to greater cortical Aβ accumulation.
BACKGROUND: We evaluated the role of cortical amyloid deposition as a factor contributing to memory dysfunction and increased risk of dementia associated with late-life depression (LLD). METHODS: A total of 119 older adult participants with a current diagnosis of major depression (LLD) from the Alzheimer's Disease Neuroimaging Initiative (ADNI) Depression Project study and 119 nondepressed (ND) cognitively unimpaired participants matched on age, sex, and APOE genotype were obtained from the ADNI database. RESULTS: Thirty-three percent of LLD participants met ADNI criteria for mild cognitive impairment. Compared with ND individuals, the LLD group exhibited less global amyloid beta (Aβ) accumulation (p = .05). The proportion of amyloid positivity in the LLD group was 19.3% compared with 31.1% for the ND participants (p = .02). Among LLD participants, global Aβ was not associated with lifetime number of depressive episodes, lifetime length of depression, length of lifetime selective serotonin reuptake inhibitor use, or lifetime length of untreated depression (p > .21 for all). Global Aβ was associated with worse memory performance (p = .05). Similar results were found in secondary analyses restricting comparisons to the cognitively unimpaired LLD participants as well as when comparing the LLD group with an ND group that included participants with mild cognitive impairment. CONCLUSIONS: Contrary to expectation, the LLD group showed less Aβ deposition than the ND group and Aβ deposition was not associated with depression history characteristics. Aβ was associated with memory, but this relationship did not differ between LLD and ND. Our results suggest that memory deficits and accelerated cognitive decline reported in previous studies of LLD are not due to greater cortical Aβ accumulation.
Authors: Mitzi M Gonzales; Jasmeet Samra; Adrienne O'Donnell; R Scott Mackin; Joel Salinas; Mini E Jacob; Claudia L Satizabal; Hugo J Aparicio; Emma G Thibault; Justin S Sanchez; Rebecca Finney; Zoe B Rubinstein; Danielle V Mayblyum; Ron J Killiany; Charlie S Decarli; Keith A Johnson; Alexa S Beiser; Sudha Seshadri Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.472
Authors: Gwenn S Smith; Hiroto Kuwabara; Ayon Nandi; Neda F Gould; Najilla Nassery; Alena Savonenko; Jin Hui Joo; Michael Kraut; James Brasic; Daniel P Holt; Andrew W Hall; William B Mathews; Robert F Dannals; Dimitrios Avramopoulos; Clifford I Workman Journal: Neurobiol Aging Date: 2021-01-15 Impact factor: 5.133
Authors: Louise Emsell; Maarten Laroy; Margot Van Cauwenberge; Thomas Vande Casteele; Kristof Vansteelandt; Koen Van Laere; Stefan Sunaert; Jan Van den Stock; Filip Bouckaert; Mathieu Vandenbulcke Journal: BMC Psychiatry Date: 2021-01-28 Impact factor: 3.630
Authors: Gwenn S Smith; Clifford I Workman; Hillary Protas; Yi Su; Alena Savonenko; Hiroto Kuwabara; Neda F Gould; Michael Kraut; Jin Hui Joo; Ayon Nandi; Dimitri Avramopoulos; Eric M Reiman; Kewei Chen Journal: Transl Psychiatry Date: 2021-09-13 Impact factor: 6.222
Authors: Nunzio Pomara; Davide Bruno; Chelsea Reichert Plaska; Jaime Ramos-Cejudo; Ricardo S Osorio; Anilkumar Pillai; Bruno P Imbimbo; Henrik Zetterberg; Kaj Blennow Journal: Transl Psychiatry Date: 2022-07-28 Impact factor: 7.989